delta-Catenin and Cell-Cell Adhesion in Prostate Cancer

前列腺癌中的 δ-连环蛋白和细胞间粘附

基本信息

  • 批准号:
    7186628
  • 负责人:
  • 金额:
    $ 18.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-03-01 至 2010-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Prostate cancer (CaP) is the most common malignancy in men in US and the second leading cause of cancer mortality. To reduce the significant morbidity and mortality, new strategies for CaP prevention and treatment depend on the determination of specific molecular mechanisms involved in this disease. ?-Catenin is a unique armadillo (ARM) domain-containing protein in that it is neural specific and primarily expresses in the brain. However, ?-catenin expression increases in prostatic adenocarcinomas, redistributes E-cadherin/p120ctn from the cell-cell junction, and promotes CaP cell growth and invasion. To investigate this largely unexplored area of neuronal catenin gene expression in peripheral tissues of cancers, the overall goal of this project is to test the hypothesis that ?-catenin promotes CaP formation and progression by interacting with multiple cellular machineries, including cell-cell and cell-matrix adhesion, cell growth/survival, and invasion. There are three specific aims in this proposal. Specific Aim 1 will determine how ?-catenin promotes cell growth/survival and motility in response to the hepatocyte growth factor and/or androgen using CWR22 tumor xenografts and their derived cell lines. We will broadly screen and profile the ?-catenin induced alteration of signaling molecules by array technology. These studies will identify cancer specific pathways that ?-catenin is involved in and will investigate their interactions with ?-catenin using protein co-immunoprecipitation and yeast two-hybrid analyses. Specific Aim 2 will determine how ?-catenin interacts with Rho family small GTPases to disrupt adherens junction and promote CaP cell growth/survival and invasion. We will first identify the ?-catenin sequence responsible for this action. Then, the analyses of ?-catenin RNAi or its mutants that are defective in Rac-1 or E-cadherin binding will determine the interactions between GTP-Rac-1/IQGAP-1 and E-cadherin/p120ctn pathways to reveal possible differential modulations on cell-cell adhesion and cell growth/survival and invasion. We will also determine the cytoplasmic accumulation and nuclear signaling of ?-catenin that is released from E-cadherin complexes by IQGAP-1. Specific Aim 3 will apply Y311, a unique (dePhospho-specific) monoclonal antibody, and site-directed mutagenesis to determine how ?-catenin modifications occur and what are their roles in CaP. We will also investigate ?-catenin proteolytic fragments and their potentials as DNA binding proteins and nuclear signaling for gene expression. Finally, we will generate transgenic mice displaying prostate tissue specific ?-catenin expression to approach these questions at the animal level. These studies will place ?-catenin into the broad context of growth factor and kinase signaling machineries relevant to CaP. Understanding the posttranslational modifications that control ?-catenin functions will unravel mechanisms by which ?-catenin modulates gene expression and promotes CaP in vivo.
描述(由申请人提供):前列腺癌(CaP)是美国男性中最常见的恶性肿瘤,也是癌症死亡的第二大原因。为了降低显著的发病率和死亡率,预防和治疗CaP的新策略依赖于确定参与这种疾病的特定分子机制。?-连环蛋白是一种独特的含有Armadillo(ARM)结构域的蛋白质,因为它是神经特异性的,主要在大脑中表达。然而,?连环蛋白在前列腺癌中表达增加,从细胞-细胞连接处重新分配E-钙粘蛋白/p120 ctn,并促进CaP细胞生长和侵袭。为了研究这一在很大程度上尚未探索的神经元连环蛋白基因在癌症外周组织中表达的领域,本项目的总体目标是检验以下假设:连环蛋白通过与多种细胞机制相互作用促进CaP形成和进展,所述细胞机制包括细胞-细胞和细胞-基质粘附、细胞生长/存活和侵袭。这项建议有三个具体目标。具体目标1将如何确定?使用CWR 22肿瘤异种移植物及其衍生细胞系,连环蛋白响应于肝细胞生长因子和/或雄激素促进细胞生长/存活和运动。我们将广泛筛选和分析?-连环蛋白诱导的信号分子的改变,通过阵列技术。这些研究将确定癌症的具体途径,连环蛋白参与并将研究它们与?使用蛋白质免疫共沉淀和酵母双杂交分析的连环蛋白。具体目标2将如何确定?连环蛋白与Rho家族小GTP酶相互作用以破坏粘附连接并促进CaP细胞生长/存活和侵袭。我们先来确认一下?-连环蛋白序列负责这一行动。然后,分析了?在Rac-1或E-cadherin结合中有缺陷的连环蛋白RNAi或其突变体将决定GTP-Rac-1/IQGAP-1和E-cadherin/p120 ctn途径之间的相互作用,以揭示对细胞-细胞粘附和细胞生长/存活和侵袭的可能差异调节。我们还将确定?的细胞质积累和核信号传导。由IQGAP-1从E-钙粘蛋白复合物释放的连环蛋白。具体目标3将应用Y311,一种独特的(去磷酸化特异性)单克隆抗体,和定点诱变来确定如何?catenin修饰的发生,以及它们在CaP中的作用。我们也会调查吗?连环蛋白蛋白水解片段及其作为DNA结合蛋白和基因表达的核信号传导的潜力。最后,我们将产生转基因小鼠显示前列腺组织特异性?catenin的表达,在动物水平上解决这些问题。这些研究将?catenin的广泛背景下的生长因子和激酶信号机制相关的钙磷。理解控制的翻译后修饰?连环蛋白的功能将解开机制,连环蛋白在体内调节基因表达并促进CaP。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

QUN LU其他文献

QUN LU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('QUN LU', 18)}}的其他基金

Homeostatic Reset as a New Therapeutic Paradigm for Slow Progression Diseases
稳态重置作为缓慢进展疾病的新治疗范式
  • 批准号:
    10273546
  • 财政年份:
    2021
  • 资助金额:
    $ 18.4万
  • 项目类别:
Homeostatic Reset as a New Therapeutic Paradigm for Slow Progression Diseases
稳态重置作为缓慢进展疾病的新治疗范式
  • 批准号:
    10689335
  • 财政年份:
    2021
  • 资助金额:
    $ 18.4万
  • 项目类别:
Homeostatic Reset as a New Therapeutic Paradigm for Slow Progression Diseases
稳态重置作为缓慢进展疾病的新治疗范式
  • 批准号:
    10796004
  • 财政年份:
    2021
  • 资助金额:
    $ 18.4万
  • 项目类别:
Homeostatic Reset as a New Therapeutic Paradigm for Slow Progression Diseases
稳态重置作为缓慢进展疾病的新治疗范式
  • 批准号:
    10488273
  • 财政年份:
    2021
  • 资助金额:
    $ 18.4万
  • 项目类别:
Rho GTPases and Neuroprotection Model in Cancer Therapy
Rho GTPases 和癌症治疗中的神经保护模型
  • 批准号:
    8232481
  • 财政年份:
    2012
  • 资助金额:
    $ 18.4万
  • 项目类别:
Rho GTPases and Neuroprotection Model in Cancer Therapy
Rho GTPases 和癌症治疗中的神经保护模型
  • 批准号:
    8769217
  • 财政年份:
    2012
  • 资助金额:
    $ 18.4万
  • 项目类别:
delta-Catenin and Cell-Cell Adhesion in Prostate Cancer
前列腺癌中的 δ-连环蛋白和细胞间粘附
  • 批准号:
    7035153
  • 财政年份:
    2006
  • 资助金额:
    $ 18.4万
  • 项目类别:
delta-Catenin and Cell-Cell Adhesion in Prostate Cancer
前列腺癌中的 δ-连环蛋白和细胞间粘附
  • 批准号:
    8068992
  • 财政年份:
    2006
  • 资助金额:
    $ 18.4万
  • 项目类别:
delta-Catenin and Cell-Cell Adhesion in Prostate Cancer
前列腺癌中的 δ-连环蛋白和细胞间粘附
  • 批准号:
    7554661
  • 财政年份:
    2006
  • 资助金额:
    $ 18.4万
  • 项目类别:
delta-Catenin and Cell-Cell Adhesion in Prostate Cancer
前列腺癌中的 δ-连环蛋白和细胞间粘附
  • 批准号:
    7345429
  • 财政年份:
    2006
  • 资助金额:
    $ 18.4万
  • 项目类别:

相似海外基金

Abnormalities in androgens and ovarian markers in reproductive-age racially and ethnically diverse women in a prospective longitudinal cohort
前瞻性纵向队列中不同种族和民族的育龄女性雄激素和卵巢标志物的异常
  • 批准号:
    10930196
  • 财政年份:
    2023
  • 资助金额:
    $ 18.4万
  • 项目类别:
Nonalcoholic Fatty Liver Disease (NAFLD) in Polycystic Ovary Syndrome: The Role of Androgens on Liver Injury and NAFLD Progression
多囊卵巢综合征中的非酒精性脂肪肝 (NAFLD):雄激素在肝损伤和 NAFLD 进展中的作用
  • 批准号:
    10735807
  • 财政年份:
    2023
  • 资助金额:
    $ 18.4万
  • 项目类别:
Sexual Differentiation of the Brain and Behaviour: Central and Peripheral Targets of Androgens
大脑和行为的性别分化:雄激素的中枢和外周目标
  • 批准号:
    RGPIN-2019-04999
  • 财政年份:
    2022
  • 资助金额:
    $ 18.4万
  • 项目类别:
    Discovery Grants Program - Individual
Elucidation of the mechanisms by which cells recognize and respond to different levels of androgens
阐明细胞识别和响应不同水平雄激素的机制
  • 批准号:
    10418461
  • 财政年份:
    2022
  • 资助金额:
    $ 18.4万
  • 项目类别:
Influence of Androgens on Tissue-Specific Lipid Metabolites and Liver Injury in Young Women with NAFLD
雄激素对患有 NAFLD 的年轻女性组织特异性脂质代谢和肝损伤的影响
  • 批准号:
    10570208
  • 财政年份:
    2022
  • 资助金额:
    $ 18.4万
  • 项目类别:
Influence of Androgens on Tissue-Specific Lipid Metabolites and Liver Injury in Young Women with NAFLD
雄激素对患有 NAFLD 的年轻女性组织特异性脂质代谢和肝损伤的影响
  • 批准号:
    10355174
  • 财政年份:
    2022
  • 资助金额:
    $ 18.4万
  • 项目类别:
Paxillin and Androgens in the Regulation of Ovarian Follicle Development
桩蛋白和雄激素在卵巢卵泡发育调节中的作用
  • 批准号:
    10688086
  • 财政年份:
    2022
  • 资助金额:
    $ 18.4万
  • 项目类别:
Defining the impact of androgens on uterine immune cell function during endometrial tissue repair
确定子宫内膜组织修复过程中雄激素对子宫免疫细胞功能的影响
  • 批准号:
    2744296
  • 财政年份:
    2022
  • 资助金额:
    $ 18.4万
  • 项目类别:
    Studentship
Use of novel 11-oxygenated androgens to improve diagnostic accuracy and therapeutics in polycystic ovary syndrome
使用新型 11-含氧雄激素提高多囊卵巢综合征的诊断准确性和治疗效果
  • 批准号:
    10431620
  • 财政年份:
    2022
  • 资助金额:
    $ 18.4万
  • 项目类别:
Paxillin and Androgens in the Regulation of Ovarian Follicle Development
桩蛋白和雄激素在卵巢卵泡发育调节中的作用
  • 批准号:
    10525097
  • 财政年份:
    2022
  • 资助金额:
    $ 18.4万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了